Comments on Final Report of the AIO Colorectal Cancer Group Study: Fluorouracil/Oxaliplatin Versus Capecitabine/Oxaliplatin
- 1 November 2007
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (31) , 5041-5042
- https://doi.org/10.1200/jco.2007.13.7158
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study GroupJournal of Clinical Oncology, 2007
- Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancerJournal of Clinical Oncology, 2007
- XELOX compared to FOLFOX4: Survival and response results from XELOX-1/ NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC)Journal of Clinical Oncology, 2007
- Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200Journal of Clinical Oncology, 2007